12/21/2017
Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort | Rh…
Article Navigation
Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis— ndings from a United Kingdom cohort Fariz Yahya , Karl Ga ney, Louise Hamilton, Ellie Lonsdale, Jane Leeder, Alan Brooksby, Charlotte Cavill, Joshua Berry-Jenkins, Cathal Boyle, Debbie Bond ... Show more Rheumatology, kex457, https://doi.org/10.1093/rheumatology/kex457 Published: 20 December 2017 Article history Cite
Permissions
Share
Abstract Objectives To analyse long-term survival and e
cacy of TNFi, reasons for switching or
discontinuing, baseline predictors of response and remission in axial spondyloarthritis (axSpA) patients in a UK cohort.
Methods All patients with a physician-veri ed diagnosis of axSpA attending two specialist centres who ful lled the eligibility criteria for TNFi were included. Routinely recorded patient data were reviewed retrospectively. Initial TNFi was recorded as the index drug.
Results Six hundred and fty-one patients (94% AS) were included; adalimumab (n = 332), etanercept (n = 205), in iximab (n = 51), golimumab (n = 40) and certolizumab pegol (n = 23) index TNFi. The mean (S .D .) duration from symptom onset to time of diagnosis Skip towere Main Content was 8.6 (8.7) years and mean (S .D .) duration from diagnosis to TNFi initiation was 12.6 (11.5) years. A total of 224 (34.4%) stopped index TNFi, and 105/224 switched to a second https://academic.oup.com/rheumatology/advance-article-abstract/doi/10.1093/rheumatology/kex457/4767791?redirectedFrom=fulltext
1/16
12/21/2017
Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort | Rh…
TNFi. Median drug survival for index and second TNFi were 10.2 years (95% CI: 8.8, 11.6 years) and 5.5 years (95% CI: 2.7, 8.3 years), respectively (P < 0.05). Survival rates were not in uenced by choice of TNFi. HLA-B27 predicted BASDAI50 and/or two or more point reduction within 6 months and long-term drug survival (P < 0.05). Low disease activity was predicted by non-smoking and low baseline BASDAI (P < 0.05).
Conclusion We have observed good TNFi survival rates in axSpA patients treated in a real-life setting. This is best for rst TNFi and not in uenced by drug choice.
Keywords: axial spondyloarthritis, TNF inhibitors, predictors, drug survival Issue Section: Concise Report
© The Author(s) 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email:
[email protected]
You do not currently have access to this article.
Comments 0 Comments
Sign in Don't already have an Oxford Academic account? Register
Oxford Academic account Email address / Username
?
Password
Skip to Main Content
Sign In
Forgot password?
https://academic.oup.com/rheumatology/advance-article-abstract/doi/10.1093/rheumatology/kex457/4767791?redirectedFrom=fulltext
2/16
